Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| AL Amyloidosis Market to Showcase Growth at a CAGR of 7.24% by 2032 | DelveInsight | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| By: PR Newswire Association LLC. - 03 Oct 2022 | Back to overview list |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
The AL amyloidosis market is expected to show positive growth owing to the factors such as increased incidence and the anticipated launch of novel therapies during the forecast period (2019–2032). LAS VEGAS, Oct. 3, 2022 /PRNewswire/ -- DelveInsight's AL Amyloidosis Market Insights report includes a comprehensive understanding of current treatment practices, AL amyloidosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].  Key Takeaways from the AL Amyloidosis Market Report
Discover which therapies are expected to grab the major AL amyloidosis market share @AL Amyloidosis Market Report AL Amyloidosis Overview Amyloid light chain (AL) amyloidosis, often known as primary amyloidosis, is the most frequent kind of systemic amyloidosis. Historically, systemic light-chain (AL) amyloidosis was assumed to be an inescapable fatal disease. Prior to successful therapies for the underlying plasma cell dyscrasia, the AL amyloidosis prognosis was poor, with an estimated AL Amyloidosis life expectancy of 13 months and just 6 months for those with symptomatic cardiac involvement. Current AL amyloidosis staging approaches focus on indicators of myocardial cell damage and heart failure indicators, which are very sensitive to cardiac involvement in amyloidosis. AL amyloidosis symptoms do not appear until the disease has advanced. The appearance of signs and symptoms is influenced by which organ is afflicted. Swelling of the ankles and legs, acute weariness and weakness, shortness of breath with minimum exercise, diarrhea, perhaps with blood, or constipation, numbness, tingling, or pain in the hands or feet, and others are the common AL amyloidosis symptoms. AL Amyloidosis Epidemiology Segmentation DelveInsight estimates that there were approximately 8.6K incident cases of AL amyloidosis in the 7MM in 2021. Among the EU5 countries, Germany had the highest number of AL amyloidosis incident cases in 2021. The AL amyloidosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Download the report to understand which factors are driving AL amyloidosis epidemiology trends @AL Amyloidosis Epidemiological Insights AL Amyloidosis Treatment Market The goal of AL amyloidosis treatment is to rapidly reduce the plasma cell clone to restore organ function by increasing amyloid reabsorption, hence improving heart function, patients' QOL, and survival. Chemotherapy (both standard and high dosage) coupled with autologous hematopoietic stem cell transplantation (ASCT) effectively reduces amyloid light chain development in appropriate people. Individuals who are ineligible for ASCT should be treated with melphalan, dexamethasone, and bortezomib-based regimens (BMDex). The National Comprehensive Cancer Network recommends high-dose melphalan followed by ASCT as one AL amyloidosis treatment option. AL amyloidosis treatment is highly individualized, based on age, organ dysfunction, and regimen toxicity, and should be guided by hematologic and cardiac response indications. Almost two-thirds of patients benefit from alkylator-based chemotherapy. Novel agents are also in use, and trials to discover the best approach to utilize them are ongoing. To know more about AL amyloidosis treatment options, visit @New Treatment for AL Amyloidosis AL Amyloidosis Pipeline Therapies and Key Companies
Learn more about the FDA-approved drugs for AL amyloidosis treatment @Drugs for AL Amyloidosis Treatment AL Amyloidosis Market Dynamics The AL amyloidosis market dynamics are anticipated to change as a result of an increase in awareness and collaboration among key industry participants (commercialization of Darzalex Faspro by Genmab and Janssen Biotech, acquisition of Caelum Biosciences by AstraZeneca in 2021). Furthermore, The robust pipeline with a novel, first-in-class therapies for AL amyloidosis treatment is one of the primary factors propelling the AL amyloidosis market growth. However, epidemiological data on AL amyloidosis is lacking, and retroactive analysis diminishes the data's legitimacy, restricting the expansion of the AL amyloidosis market. Furthermore, the diseases' complicated heterogeneity causes delays in diagnosis, resulting in severe disease (organ dysfunction - heart, kidney, liver), reducing AL amyloidosis survival rates, and serving as a barrier to the growth of the AL amyloidosis market. Moreover, due to poor patient recruitment and a lack of clearly defined new outcomes, AL amyloidosis clinical trials are challenging to conduct. The involvement of the cardiac and renal organs leads to a high treatment cost. In addition, the expected launches are likely to be more expensive than myeloma-based drugs, restricting the availability and affordability of AL amyloidosis treatments. Furthermore, in the age of daratumumab-based frontline treatment, the role of upfront ASCT in eligible patients must be clarified. As a result, the aforementioned factors impede the AL amyloidosis market growth.
Scope of the AL Amyloidosis Market Report
Discover more about drugs for AL amyloidosis in development @AL Amyloidosis Clinical Trials Table of Contents
Related Reports AL Amyloidosis Epidemiology Forecast AL Amyloidosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the AL amyloidosis epidemiology trends. AL Amyloidosis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key AL amyloidosis companies, including Acrotech biopharma, Sanofi, Astellas Pharma GmbH, Prothena, Alexion Pharmaceuticals, Celgene Corporation, among others. Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others. Multiple Myeloma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others. Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Hodgkin lymphoma companies, including 4SC, ACD Therapeutics, TG Therapeutics, among others. Hodgkin Lymphoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Hodgkin lymphoma companies, including 4SC, ACD Therapeutics, TG Therapeutics, among others. Other Trending Reports Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market Browse through our latest blog to get more insights on AL Amyloidosis Treatment Landscape About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services Contact Us Shruti Thakur Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 | Back to overview list | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View original content: